ClearPoint Neuro, Inc.

CLPT

HealthcareMedical - DevicesNASDAQ

$12.82

Market Cap: $384.42M

ClearPoint Neuro, Inc. (CLPT) Valuation Summary

Updated May 11, 2026 21:07

Model	Range	Fair Value	Upside
▸ Discounted Cash Flow
Revenue DCF 5Y	—	N/A	—
Revenue DCF 10Y	$0.04 – $13.45	$1.63	-87.3%
▸ Trading Multiples
EV/Revenue	$0.73 – $3.02	$1.55	-87.9%

Valuation History

DCF Analysis

ClearPoint Neuro, Inc. (CLPT) Revenue DCF (5Y)

REVENUE DCF FAIR VALUE

$1.63

Market Price

$12.82

Upside / Downside

-87.3%

Verdict

Overvalued

Using a Revenue DCF model with operating margin convergence from -65.4% to a target of 13.2% over 5 years, discounted at a WACC of 8.1%, ClearPoint Neuro, Inc. (CLPT) has an intrinsic value of $1.63 per share (range: $0.04 – $13.45).

Key Assumptions

Current Operating Margin

-65.4%

Target Operating Margin

13.2%

WACC

8.1%

Terminal Growth Rate

3.0%

Historical CapEx/Rev

1.5%

Target CapEx/Rev

6.9%

D&A/Revenue

4.6%

Tax Rate

21.0%

Operating margin fades linearly from the current level to the industry target over the 5-year projection. CapEx intensity fades from the historical average to a maintenance level (D&A × 1.5). Tax is only applied when operating income is positive (NOL shield).

Margin Convergence Projection

USD in millions. Mid-year discounting convention.

Year	Revenue	Growth	Op Margin	Op Income	NOPAT	D&A	CapEx	ΔNWC	FCFF	PV(FCFF)
2026	53	42.8%	-49.6%	-26	-26	2	(1)	9	-34	-32
2027	63	19.5%	-33.9%	-21	-21	3	(2)	4	-25	-22
2028	77	22.7%	-18.2%	-14	-14	4	(2)	6	-19	-16
2029	95	22.7%	-2.5%	-2	-2	4	(3)	8	-9	-7
2030	117	22.7%	13.2%	15	12	5	(5)	9	3	2
2031	139	19.4%	13.2%	18	15	6	(7)	10	4	3
2032	162	16.1%	13.2%	21	17	7	(9)	10	6	4
2033	183	12.9%	13.2%	24	19	8	(11)	9	8	4
2034	200	9.6%	13.2%	26	21	9	(13)	8	10	5
2035	213	6.3%	13.2%	28	22	10	(15)	5	12	6

Enterprise Value Bridge

Sum of PV(FCFF)-53

Terminal Value (Gordon Growth at 3.0%)236

PV of Terminal Value112

Enterprise Value59

(–) Net Debt12

Equity Value46

(÷) Shares Outstanding28

Fair Value per Share$1.63

Sensitivity Analysis — WACC × Target Operating Margin

WACC \ Target Op. Margin	7.2%	10.2%	13.2%	16.2%	19.2%
6.1%	$-3	$1	$5	$9	$13
7.1%	$-3	$0	$3	$6	$9
8.1%	$-3	$-1	$2	$4	$6
9.1%	$-3	$-1	$1	$3	$4
10.1%	$-3	$-2	$0	$2	$3

Current price: $12.82. Green = undervalued, Red = overvalued.

Working Capital Assumption

Net Working Capital is modeled at 43.6% of revenue (historical average of receivables + inventory − payables). Changes in NWC (ΔNWC) are computed year-over-year and subtracted from free cash flow.

Trading Multiples

Fair Value

$1.55

Market Price

$12.82

Upside / Downside

-87.9%

Verdict

Overvalued

Using the industry peer median EV/Revenue multiple (trailing + forward), ClearPoint Neuro, Inc. (CLPT) has a fair value of $1.55 based on 7 comparable companies in the Medical - Devices industry.

EV/Revenue Valuation — Medical - Devices

USD in millions except Fair Price. Subject company highlighted.

	Mkt Cap ($M)	Trailing EV/Revenue	Forward EV/Revenue
ClearPoint Neuro, Inc.CLPT	363	10.2x	13.4x
Avanos Medical, Inc.AVNS	1,161	1.7x	1.8x
Cytek Biosciences, Inc.CTKB	593	2.6x	2.7x
SI-BONE, Inc.SIBN	573	2.6x	2.3x
Varex Imaging CorporationVREX	496	0.9x	0.9x
Orthofix Medical Inc.OFIX	471	0.8x	0.7x
Standard BioTools Inc.LAB	398	3.6x	1.8x
Akebia Therapeutics, Inc.AKBA	311	1.5x	1.5x
Industry Median		1.7x	1.8x
(*) Revenue		37	28
= Enterprise Value		63	49
(-) Net Debt		12	12
Equity Value		51	37
(/) Outstanding shares		28	28
Fair Price		$2	$1

Selected Fair Value (avg of trailing + forward)

$1.55

-87.9%

Disclaimer: Sweet Value Lab provides estimated intrinsic values for informational purposes only. This is not financial advice. All models rely on assumptions that may not reflect future performance. Always do your own research before making investment decisions.

Model

Range

Fair Value

Upside

▸ Discounted Cash Flow

Revenue DCF 5Y

—

N/A

—

Revenue DCF 10Y

$0.04 – $13.45

$1.63

-87.3%

▸ Trading Multiples

EV/Revenue

$0.73 – $3.02

$1.55

-87.9%

DCF Analysis

ClearPoint Neuro, Inc. (CLPT) Revenue DCF (5Y)

REVENUE DCF FAIR VALUE

$1.63

Market Price

$12.82

Upside / Downside

-87.3%

Verdict

Overvalued

Key Assumptions

Current Operating Margin

-65.4%

Target Operating Margin

13.2%

WACC

8.1%

Terminal Growth Rate

3.0%

Historical CapEx/Rev

1.5%

Target CapEx/Rev

6.9%

D&A/Revenue

4.6%

Tax Rate

21.0%

Margin Convergence Projection

USD in millions. Mid-year discounting convention.

Year	Revenue	Growth	Op Margin	Op Income	NOPAT	D&A	CapEx	ΔNWC	FCFF	PV(FCFF)
2026	53	42.8%	-49.6%	-26	-26	2	(1)	9	-34	-32
2027	63	19.5%	-33.9%	-21	-21	3	(2)	4	-25	-22
2028	77	22.7%	-18.2%	-14	-14	4	(2)	6	-19	-16
2029	95	22.7%	-2.5%	-2	-2	4	(3)	8	-9	-7
2030	117	22.7%	13.2%	15	12	5	(5)	9	3	2
2031	139	19.4%	13.2%	18	15	6	(7)	10	4	3
2032	162	16.1%	13.2%	21	17	7	(9)	10	6	4
2033	183	12.9%	13.2%	24	19	8	(11)	9	8	4
2034	200	9.6%	13.2%	26	21	9	(13)	8	10	5
2035	213	6.3%	13.2%	28	22	10	(15)	5	12	6

Enterprise Value Bridge

Sum of PV(FCFF)-53

Terminal Value (Gordon Growth at 3.0%)236

PV of Terminal Value112

Enterprise Value59

(–) Net Debt12

Equity Value46

(÷) Shares Outstanding28

Fair Value per Share$1.63

Sensitivity Analysis — WACC × Target Operating Margin

WACC \ Target Op. Margin	7.2%	10.2%	13.2%	16.2%	19.2%
6.1%	$-3	$1	$5	$9	$13
7.1%	$-3	$0	$3	$6	$9
8.1%	$-3	$-1	$2	$4	$6
9.1%	$-3	$-1	$1	$3	$4
10.1%	$-3	$-2	$0	$2	$3

Current price: $12.82. Green = undervalued, Red = overvalued.

Working Capital Assumption

Net Working Capital is modeled at 43.6% of revenue (historical average of receivables + inventory − payables). Changes in NWC (ΔNWC) are computed year-over-year and subtracted from free cash flow.

Trading Multiples

Fair Value

$1.55

Market Price

$12.82

Upside / Downside

-87.9%

Verdict

Overvalued

Using the industry peer median EV/Revenue multiple (trailing + forward), ClearPoint Neuro, Inc. (CLPT) has a fair value of $1.55 based on 7 comparable companies in the Medical - Devices industry.

EV/Revenue Valuation — Medical - Devices

USD in millions except Fair Price. Subject company highlighted.

	Mkt Cap ($M)	Trailing EV/Revenue	Forward EV/Revenue
ClearPoint Neuro, Inc.CLPT	363	10.2x	13.4x
Avanos Medical, Inc.AVNS	1,161	1.7x	1.8x
Cytek Biosciences, Inc.CTKB	593	2.6x	2.7x
SI-BONE, Inc.SIBN	573	2.6x	2.3x
Varex Imaging CorporationVREX	496	0.9x	0.9x
Orthofix Medical Inc.OFIX	471	0.8x	0.7x
Standard BioTools Inc.LAB	398	3.6x	1.8x
Akebia Therapeutics, Inc.AKBA	311	1.5x	1.5x
Industry Median		1.7x	1.8x
(*) Revenue		37	28
= Enterprise Value		63	49
(-) Net Debt		12	12
Equity Value		51	37
(/) Outstanding shares		28	28
Fair Price		$2	$1

Selected Fair Value (avg of trailing + forward)

$1.55

-87.9%